Buying guide
Apple Watch vs Happy Ring in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Apple | Happy Health |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | internal-onlyenterprise |
| Price | $399-$799 (actual sale price) | Not announced |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 1Apple | 0 |
| Privacy practices | 13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage | — |
| Sources on file | 26 | 7 |
Editorial summaries
Apple Watch
The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.
Happy Ring
The Happy Ring (from Happy Health Inc, Austin, Texas; CEO Dustin Freckleton, MD) is the FDA-cleared, service-gated archetype of the ring sub-cohort, and the sharpest verified-vs-claimed counterpoint to RingConn: the same finger-ring form factor and similar sleep-apnea capability claims, but a diametrically opposite verification posture. Its cleared sleep-apnea algorithm is the regulatory substance, with two dated FDA 510(k) clearances: K240236 (October 8, 2024) for retrospective remote monitoring of physiological parameters in adults at home or in healthcare facilities; and K242224 (June 18, 2025) for a Home Sleep Test that processes the ring's signals for clinician-interpreted diagnosis of sleep disorders such as obstructive sleep apnea and insomnia, ages 22+, under the direction of a trained healthcare provider (clinician-directed, not autonomous diagnosis). It is not a standalone retail ring: it is sold only bundled into the clinician-reviewed, insurer-billed 'Happy Sleep' home-sleep-test service, so there is no published consumer price. Cap-flags: a 97% agreement with polysomnography is company-reported with no peer-reviewed citation; the 'brain biometrics' marketing is not substantiated by any named EEG hardware; and funding is a $60M Series A (August 2022, ARCH Venture Partners) with no later round surfaced, an early-stage state.
Machine-readable: this page as markdown.